Last reviewed · How we verify
Paradione (PARAMETHADIONE)
Paradione (Paramethadione) is a small molecule drug that targets voltage-gated T-type calcium channels. It was originally developed and is currently owned by a company not specified in the provided facts. Paradione is used to treat absence seizures and epilepsy, and was FDA approved in 1949. It is off-patent and has no active Orange Book patents, meaning it is available as a generic medication. However, there are no generic manufacturers listed.
At a glance
| Generic name | PARAMETHADIONE |
|---|---|
| Drug class | paramethadione |
| Target | Voltage-gated T-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1949 |
Approved indications
- Absence seizure
- Epilepsy
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |